Anteris Technologies Global Corp. (“ATGC”) today announced the pricing of its initial public offering (“IPO”) of 14,800,000 shares of its common stock in the United States. The shares have been priced at $6.00 per share. Trading of the shares is expected to commence on December 13, 2024 on the Nasdaq Global Market under the ticker symbol “AVR”. The offering is expected to close on December 16, 2024 subject to satisfaction of customary closing conditions.
The IPO shall consist entirely of shares being sold by ATGC. ATGC granted the underwriters a 30-day option to buy up to an additional 2,220,000 shares at the IPO price, net of underwriting discounts and commissions. The net proceeds of the offering together with available cash and cash equivalents shall further be used for further continued development of ATGC’s transcatheter heart valve.
The company is planning the global pivotal study on its THV to be ready and enroll participants to get to market in this indicated application for the treatment of severe aortic stenosis. The remaining proceeds will be used for working capital and other general corporate purposes, including the repayment of obligations under ATGC’s convertible note facility.
TD Cowen, Barclays, and Cantor are acting as joint book-running managers in the offering, with Lake Street Capital Markets as lead manager. The ATGC intends to list CDIs representing its common stock on the Australian Securities Exchange (“ASX”) under the symbol “AVR”, in addition to listing on U.S.
A registration statement for these securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on December 12, 2024. The offering is being made only by means of a prospectus. Copies of the final prospectus, once available, may be obtained by contacting the underwriters at the telephone numbers or addresses listed below. The current issuance is for informational purposes alone and, therefore, should not be considered as an offer to sell or a solicitation of an offer to buy any securities. The offer or sale of the securities will be made in accordance with the laws that apply.
